Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 7/20 | 0.84 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.84 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278663 | 0.94 | PTGES (0.84) | PTGESALOX5ESR1ALDH1A1LMNA | |
| SCHEMBL1279470 | 0.87 | PTGES (0.80) | PTGESALOX5ALDH1A1LMNAMEN1 | |
| SCHEMBL1279330 | 0.87 | TAS2R14 (0.74) | PTGESALOX5ALDH1A1LMNAKMT2A | |
| SCHEMBL5330652 | 0.85 | ESR1 (0.78) | PTGESALOX5ESR1ALDH1A1LMNA | |
| SCHEMBL1711098 | 0.85 | MEN1 (0.76) | PTGESALOX5ALDH1A1LMNAMEN1 | |
| SCHEMBL2774329 | 0.85 | TAS2R14 (0.74) | PTGESALOX5ALDH1A1LMNAMEN1 | |
| SCHEMBL27593108 | 0.84 | ESR1 (1.00) | PTGESALOX5ESR1ALDH1A1LMNA | |
| SCHEMBL10250146 | 0.84 | LMNA (1.00) | PTGESALOX5ESR1ALDH1A1LMNA | |
| SCHEMBL2189346 | 0.84 | LMNA (0.85) | PTGESALOX5ESR1ALDH1A1LMNA | |
| SCHEMBL1278616 | 0.83 | TAS2R14 (1.00) | PTGESMEN1KMT2ATAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057116-B1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2013-01-31 | — | — | US | disclosed |
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2012-11-22 | — | — | US | disclosed |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-29 | — | — | US | disclosed |
| EP-2057116-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008050167-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | PTGES 618/4885ALOX5 919/4885ESR1 1046/4885 |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | PTGES 540/4885ALOX5 895/4885ESR1 1054/4885 |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | PTGES 532/4885ALOX5 949/4885ESR1 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.